tiprankstipranks
Trending News
More News >
Aquestive Therapeutics (AQST)
NASDAQ:AQST
US Market

Aquestive Therapeutics (AQST) Stock Forecast & Price Target

Compare
2,165 Followers
See the Price Targets and Ratings of:

AQST Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Aquestive
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AQST Stock 12 Month Forecast

Average Price Target

$7.59
▲(112.61%Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Aquestive Therapeutics in the last 3 months. The average price target is $7.59 with a high forecast of $10.00 and a low forecast of $4.75. The average price target represents a 112.61% change from the last price of $3.57.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","3.5":"$3.5","8.5":"$8.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.59,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.5,6,8.5,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.81,3.363076923076923,3.916153846153846,4.469230769230769,5.022307692307692,5.575384615384616,6.128461538461538,6.6815384615384605,7.234615384615385,7.787692307692307,8.340769230769231,8.893846153846154,9.446923076923076,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.81,3.1776923076923076,3.5453846153846156,3.913076923076923,4.280769230769231,4.648461538461538,5.016153846153847,5.383846153846154,5.751538461538461,6.119230769230769,6.486923076923077,6.854615384615384,7.222307692307693,{"y":7.59,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.81,2.959230769230769,3.1084615384615386,3.2576923076923077,3.4069230769230767,3.556153846153846,3.7053846153846153,3.8546153846153848,4.003846153846154,4.153076923076923,4.302307692307693,4.451538461538462,4.600769230769231,{"y":4.75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.88,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.59,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.53,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.81,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$10.00Average Price Target$7.59Lowest Price Target$4.75
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on AQST
TipRanks AITipRanks
Not Ranked
TipRanks
$3.5
Hold
-1.96%
Downside
Reiterated
06/05/25
Aquestive Therapeutics currently faces significant financial and operational challenges. The most critical risk factors include declining revenues, negative profit margins, and high leverage. While technical indicators show potential short-term momentum, valuation metrics and corporate events reveal underlying financial difficulties that hinder long-term prospects.
Oppenheimer
$15$7
Buy
96.08%
Upside
Initiated
06/02/25
Aquestive Therapeutics price target lowered to $7 from $15 at OppenheimerAquestive Therapeutics price target lowered to $7 from $15 at Oppenheimer
H.C. Wainwright Analyst forecast on AQST
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
$10
Buy
180.11%
Upside
Reiterated
05/15/25
Buy Recommendation for Aquestive Therapeutics: Promising Prospects for Anaphylm's Market Launch and Growth
Lake Street Analyst forecast on AQST
Thomas FlatenLake Street
Lake Street
$10$8
Buy
124.09%
Upside
Reiterated
05/14/25
Lake Street Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)
Leerink Partners Analyst forecast on AQST
Roanna RuizLeerink Partners
Leerink Partners
$12$10
Buy
180.11%
Upside
Reiterated
05/14/25
Strategic Shift and Financial Positioning Drive Buy Rating for Aquestive Therapeutics Amid Anaphylm Launch PreparationsWe updated our model for the 1Q25 print (details below), which lowered our PT to $10 (vs $12 prior). Reit. OP.
Alliance Global Partners Analyst forecast on AQST
James MolloyAlliance Global Partners
Alliance Global Partners
$4.75
Buy
33.05%
Upside
Reiterated
05/14/25
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (NASDAQ: ATXS), Aquestive Therapeutics (NASDAQ: AQST) and Olema Pharmaceuticals (NASDAQ: OLMA)
Piper Sandler Analyst forecast on AQST
David AmsellemPiper Sandler
Piper Sandler
$8$5
Buy
40.06%
Upside
Reiterated
05/13/25
Aquestive Therapeutics price target lowered to $5 from $8 at Piper SandlerAquestive Therapeutics price target lowered to $5 from $8 at Piper Sandler
Raymond James Analyst forecast on AQST
Gary NachmanRaymond James
Raymond James
$7
Buy
96.08%
Upside
Reiterated
05/13/25
Raymond James reiterates Outperform Rating on Aquestive Therapeutics (AQST)Raymond James analyst Gary Nachman reiterated an Outperform rating and $7.00 price target on Aquestive Therapeutics (NASDAQ: AQST).
Citizens JMP Analyst forecast on AQST
Jason ButlerCitizens JMP
Citizens JMP
$9
Buy
152.10%
Upside
Reiterated
04/01/25
Aquestive Therapeutics' Anaphylm NDA Submission and Strong Clinical Profile Support Buy Rating
Cantor Fitzgerald Analyst forecast on AQST
Kristen KluskaCantor Fitzgerald
Cantor Fitzgerald
$17
Buy
376.19%
Upside
Initiated
12/17/24
Aquestive Therapeutics initiated with an Overweight at Cantor FitzgeraldAquestive Therapeutics initiated with an Overweight at Cantor Fitzgerald
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on AQST
TipRanks AITipRanks
Not Ranked
TipRanks
$3.5
Hold
-1.96%
Downside
Reiterated
06/05/25
Aquestive Therapeutics currently faces significant financial and operational challenges. The most critical risk factors include declining revenues, negative profit margins, and high leverage. While technical indicators show potential short-term momentum, valuation metrics and corporate events reveal underlying financial difficulties that hinder long-term prospects.
Oppenheimer
$15$7
Buy
96.08%
Upside
Initiated
06/02/25
Aquestive Therapeutics price target lowered to $7 from $15 at OppenheimerAquestive Therapeutics price target lowered to $7 from $15 at Oppenheimer
H.C. Wainwright Analyst forecast on AQST
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
$10
Buy
180.11%
Upside
Reiterated
05/15/25
Buy Recommendation for Aquestive Therapeutics: Promising Prospects for Anaphylm's Market Launch and Growth
Lake Street Analyst forecast on AQST
Thomas FlatenLake Street
Lake Street
$10$8
Buy
124.09%
Upside
Reiterated
05/14/25
Lake Street Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)
Leerink Partners Analyst forecast on AQST
Roanna RuizLeerink Partners
Leerink Partners
$12$10
Buy
180.11%
Upside
Reiterated
05/14/25
Strategic Shift and Financial Positioning Drive Buy Rating for Aquestive Therapeutics Amid Anaphylm Launch PreparationsWe updated our model for the 1Q25 print (details below), which lowered our PT to $10 (vs $12 prior). Reit. OP.
Alliance Global Partners Analyst forecast on AQST
James MolloyAlliance Global Partners
Alliance Global Partners
$4.75
Buy
33.05%
Upside
Reiterated
05/14/25
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (NASDAQ: ATXS), Aquestive Therapeutics (NASDAQ: AQST) and Olema Pharmaceuticals (NASDAQ: OLMA)
Piper Sandler Analyst forecast on AQST
David AmsellemPiper Sandler
Piper Sandler
$8$5
Buy
40.06%
Upside
Reiterated
05/13/25
Aquestive Therapeutics price target lowered to $5 from $8 at Piper SandlerAquestive Therapeutics price target lowered to $5 from $8 at Piper Sandler
Raymond James Analyst forecast on AQST
Gary NachmanRaymond James
Raymond James
$7
Buy
96.08%
Upside
Reiterated
05/13/25
Raymond James reiterates Outperform Rating on Aquestive Therapeutics (AQST)Raymond James analyst Gary Nachman reiterated an Outperform rating and $7.00 price target on Aquestive Therapeutics (NASDAQ: AQST).
Citizens JMP Analyst forecast on AQST
Jason ButlerCitizens JMP
Citizens JMP
$9
Buy
152.10%
Upside
Reiterated
04/01/25
Aquestive Therapeutics' Anaphylm NDA Submission and Strong Clinical Profile Support Buy Rating
Cantor Fitzgerald Analyst forecast on AQST
Kristen KluskaCantor Fitzgerald
Cantor Fitzgerald
$17
Buy
376.19%
Upside
Initiated
12/17/24
Aquestive Therapeutics initiated with an Overweight at Cantor FitzgeraldAquestive Therapeutics initiated with an Overweight at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aquestive Therapeutics

1 Month
xxx
Success Rate
9/15 ratings generated profit
60%
Average Return
+4.13%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +4.13% per trade.
3 Months
xxx
Success Rate
11/17 ratings generated profit
65%
Average Return
+18.92%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +18.92% per trade.
1 Year
Jason ButlerCitizens JMP
Success Rate
21/36 ratings generated profit
58%
Average Return
+44.36%
reiterated a buy rating 2 months ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +44.36% per trade.
2 Years
xxx
Success Rate
24/36 ratings generated profit
67%
Average Return
+87.41%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +87.41% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AQST Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
10
13
13
16
9
Buy
2
1
1
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
14
14
17
10
In the current month, AQST has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AQST average Analyst price target in the past 3 months is 7.59.
Each month's total comprises the sum of three months' worth of ratings.

AQST Financial Forecast

AQST Earnings Forecast

Next quarter’s earnings estimate for AQST is -$0.17 with a range of -$0.22 to -$0.14. The previous quarter’s EPS was -$0.24. AQST beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year AQST has Outperformed its overall industry.
Next quarter’s earnings estimate for AQST is -$0.17 with a range of -$0.22 to -$0.14. The previous quarter’s EPS was -$0.24. AQST beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year AQST has Outperformed its overall industry.

AQST Sales Forecast

Next quarter’s sales forecast for AQST is $11.32M with a range of $10.04M to $12.40M. The previous quarter’s sales results were $8.72M. AQST beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year AQST has Outperformed its overall industry.
Next quarter’s sales forecast for AQST is $11.32M with a range of $10.04M to $12.40M. The previous quarter’s sales results were $8.72M. AQST beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year AQST has Outperformed its overall industry.

AQST Stock Forecast FAQ

What is AQST’s average 12-month price target, according to analysts?
Based on analyst ratings, Aquestive Therapeutics’s 12-month average price target is 7.59.
    What is AQST’s upside potential, based on the analysts’ average price target?
    Aquestive Therapeutics has 112.61% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AQST a Buy, Sell or Hold?
          Aquestive Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Aquestive Therapeutics’s price target?
            The average price target for Aquestive Therapeutics is 7.59. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $10.00 ,the lowest forecast is $4.75. The average price target represents 112.61% Increase from the current price of $3.57.
              What do analysts say about Aquestive Therapeutics?
              Aquestive Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of AQST?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis